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Background: The treatment of complicated skin and soft tissue infections (cSSTI) is challenging and many patients
do not receive adequate first-line therapy. REACH (REtrospective Study to Assess the Clinical Management of
Patients With Moderate-to-Severe cSSTI or Community-Acquired Pneumonia in the Hospital Setting) was a
retrospective observational study of cSSTI patients in real-life settings in European hospitals. In this analysis,
we review characteristics and outcomes of patients with an early response (≤72 hours) compared with those
without an early response to treatment. We also compare the results according to two differing definitions of
early response, one of which (Definition 1) requires resolution of fever within 72 hours, in line with previous
US FDA guidelines.
Methods: Patients were adults hospitalized with cSSTIs 2010–2011 and requiring treatment with intravenous
antibiotics. Clinical management, clinical outcomes and healthcare resource use were assessed using a
descriptive analysis approach.
Results: The analysis set included 600 patients, of which 363 showed early response with Definition 1 and
417 with Definition 2. Initial treatment modification was frequent, and highest in patients without early
response (48.1% with Definition 1). Patients without early response were more likely to have diabetes than
those with early response (31.6% vs. 22.9%, respectively) and to suffer from more severe disease (e.g. skin
necrosis: 14.8% and 7.7%, respectively), to be infected with difficult-to-treat microorganisms and to have recurrent
infections. Furthermore, patients without early response had a higher rate of adverse clinical outcomes (e.g. septic
shock) and higher use of healthcare resources. The results obtained with the two definitions for early response were
largely similar.
Conclusions: This study highlights the significance of early evaluation of patients in hospitals, in potentially preventing
prolonged use of inappropriate or ineffective antibacterial therapy.
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Complicated skin and soft tissue infections (cSSTIs) rep-
resent a heterogeneous range of diseases, from severe
infections affecting otherwise healthy patients, to rela-
tively minor infections affecting patients with several co-
morbidities [1]. cSSTIs are reported to be among the most
common infections treated in the hospital setting [2],
both in the UK, where they account for at least 10% of
admissions to infection units [3], and in the USA, where
hospital admissions for cSSTI increased by 29% from
2000–2004 [4].
Treatment of cSSTIs is typically empirical, and earlier
studies have shown high rates of initial treatment failure
in patients hospitalized with cSSTI [5,6]. Until recently,
clinical trials evaluating antibacterial agents for treat-
ment of cSSTI incorporated clinical cure as a primary
endpoint. Clinical cure has traditionally been defined as
total resolution of all signs and symptoms of the infec-
tion or improvement to such an extent that no further
antimicrobial therapy is necessary [7,8]. In 2010, the US
Food and Drug Administration (FDA) issued draft guid-
ance recommending a new primary endpoint for industrial
development of antimicrobials used for the treatment of
acute bacterial skin and soft structure infection (ABSSSI)
to be defined at 48–72 hours instead of the traditional
test-of-cure [9]. This earlier time point could be more
clinically relevant, as it would allow early identification of
treatment success or failure and prevent prolonged use of
inappropriate or ineffective antibacterial therapy, which is
shown to be associated with adverse outcomes [6]. The
FDA recommended endpoint includes co-primary out-
comes of the resolution of fever and the cessation of the
spread of the lesion after approximately 48–72 hours of
antibacterial therapy [9].
The REACH study systematically collected real-life,
current (2010–2011), pan-European data, on patients
hospitalized for cSSTIs. This subanalysis aimed to evalu-
ate the characteristics of patients with an early response
to treatment (≤72 hours) compared with those without,
according to two differing definitions of early response,
and to identify any impact of an early response on clin-
ical and economic outcomes.
Methods
REACH (NCT01293435) was a retrospective, observa-
tional study of patients hospitalized with cSSTI and re-
ceiving intravenous (IV) antibiotic treatment. It enrolled
1,995 patients aged ≥18 years, from 129 sites in 10 partici-
pating countries across Europe (Belgium, France, Germany,
Greece, Italy, the Netherlands, Portugal, Spain, Turkey
and the UK). Further information on hospital sites is pro-
vided in Additional file 1: Table S1. Data detailing pa-
tient demographics, disease characteristics, microbiological
diagnosis, disease course and outcomes, treatments beforeand during hospitalization and health resource consump-
tion were collected via an electronic Case Report Form
(eCRF). The study was performed according to Good
Clinical Practice and the Declaration of Helsinki. All local
ethics committees approved the study protocol. A list
of ethics committees is provided in Additional file 2.
Local legislation relating to written informed consent for
non-interventional studies was followed in each country;
in Germany and Portugal, where this information is
mandatory, written informed consent was collected.
Patients were required to have an infection affecting deeper
soft tissue and/or requiring significant surgical intervention,
an infection developing on a lower limb in subjects with
diabetes mellitus or well-documented peripheral vascular
disease, a major abscess, an infected ulcer, or deep and
extensive cellulitis. Study design and patient inclusion
and exclusion criteria are described in the primary publi-
cation for this study [10]. In short, patients were selected
from the total number of patients admitted to hospital
within that time frame with cSSTI, using an automatic
randomization tool. The selected patients were then
assessed for eligibility by conducting a first review of
the medical charts. Patients who did not meet the prede-
fined criteria of cSSTI (detailed in Additional file 1) or
who did not require IV antibiotics were excluded. The rest
were enrolled. Further inclusion and exclusion criteria are
detailed in Additional file 1.
Initial treatment modification (ITM) was defined as a
change from initial antibiotic treatment to a new anti-
biotic treatment due to insufficient response, adverse
reaction, interaction with other drugs, non-suitability
of the initial antibiotic based on the results of micro-
biological tests, changes in antibiotic therapy, or addition
of further agents alone or in combination. No time
limit was included in the definition. Cases of stream-
lining or de-escalation (defined as a change to narrower-
spectrum antibiotics upon patient improvement or
confirmed microbiological diagnosis) were not counted as
ITM [10].
This subanalysis focuses on the characteristics, anti-
biotic treatments, clinical outcomes and use of healthcare
resources of patients from the REACH study who achieved
early response to treatment, compared with those who did
not, as assessed by the responses to the following questions
in the eCRF:
 Q1: Resolution of fever within the 72-hour period
since initial antibiotic therapy;
 Q2: Documented indication of lesion improvement
within the 72-hour period since initial antibiotic
therapy;
 Q3: Cessation of spread of redness, oedema and/or
induration of lesion within the 72-hour period since
initial antibiotic therapy;
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induration within the 72-hour period since initial
antibiotic therapy;
 Q5: Disappearance of local signs/symptoms present
at admission within the 72-hour period since initial
antibiotic therapy.
Early response was evaluated by two definitions; Defin-
ition 1 (D1; in line with the FDA draft guidance) [9] re-
quired resolution of fever and some indication of lesion
improvement or stability within 72 hours of treatment
initiation, i.e. a positive response to Q1 and Q2, Q3 or
Q4. To address Q1, patients had to have fever at presen-
tation. Definition 2 (D2) required evidence of lesion
improvement or stability, or resolution of signs and symp-
toms within 72 hours, i.e. a positive response to Q2, Q3,
Q4 or Q5, but did not include fever resolution as a
requirement, as suggested by the Foundation for the
National Institute of HealthBiomarkers Consortium [11].
Characteristics of patients showing early response to
treatment (≤72 hours), defined by both D1 and D2, were
compared with those of patients without early response,
and corresponding outcomes and resource use mea-
sured. Only patients with available data in their medical
records, sufficient to be classified according to each of
these definitions, were included in this subanalysis.
Statistical methods
This was a non-interventional study, using a descriptive
analysis approach to assess clinical management, clinical
outcomes and healthcare resource use.TOTAL
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Figure 1 Patient classification with Definition 1 and Definition 2. Gree
red denotes patients without an early response and yellow is used for unk
classification with the two definitions.Results
Patient population
Of 1,995 patients enrolled in the REACH study, 1,513
(76%) had information detailing response to treatment
recorded (Additional file 1: Table S2). The analysis set
included 600 patients who had available data for assess-
ment by D1 (Figure 1). A total of 363 (60.5%) of these
patients were classified as early responders, while 237
(39.5%) were not. When D2 was used, an additional 54
(9%) patients were classified as early responders. This
change in response outcome under the alternative defin-
ition was due to the fever resolution criterion in Q1 (47
patients) and to symptom resolution in Q5 (7 patients).
Regardless of the consideration of fever resolution, 553/
600 patients (92.2%) were included in the same classifica-
tion. Therefore, including fever resolution restricted the
number of patients who met the definition for early re-
sponse, but the outcomes were largely unaffected.
Patient demographics, medical history and disease
characteristics are shown in Table 1. The most common
lesion types were cellulitis/fasciitis (approximately half of
patients); abscess (one-fifth); and post-traumatic wound,
post-surgical wound, diabetic leg ulcer or peripheral vas-
cular disease ulcer (all around 5–10%). Approximately
20–25% had a recurrent skin infection and 8–10% a noso-
comial infection. Demographics were similar between pa-
tients with and without an early response by both
definitions, but patients without an early response were
more likely to have diabetes than patients with (D1: 31.6%
and 22.9%, respectively), and more severe disease (e.g. skin











n denotes patients with an early response to treatment (≤72 hours),
nowns. Mixed colours indicate those patients who had a different
Table 1 Patient demographics, medical history and disease characteristics
Definition 1 Definition 2
Characteristic, n (%) Early responders Not early responders Early responders Not early responders
n = 363 n = 237 n = 417 n = 173
Age, years, mean (SD) [median] 58.5 (17.72) [58.0] 58.2 (17.17) [59.0] 58.9 (17.78) [58.0] 57.2 (17.08) [58.5]
<65 years 227 (62.5) 146 (61.6) 253 (60.7) 114 (65.9)
≥65 years 136 (37.5) 90 (38.0) 164 (39.3) 58 (33.5)
Sex, male 211 (58.1) 143 (60.3) 239 (57.3) 108 (62.4)
Relevant medical conditions affecting <10% of patients at hospitalization (initial visit*), n (%)
Diabetes 83 (22.9) 75 (31.6) 103 (24.7) 50 (28.9)
Cancer/malignancy 62 (17.1) 29 (12.2) 69 (16.5) 19 (11.0)
Peripheral vascular disease 55 (15.2) 37 (15.6) 68 (16.3) 20 (11.6)
Congestive heart disease 47 (12.9) 30 (12.7) 58 (13.9) 18 (10.4)
Other relevant conditions† 100 (27.5 ) 84 (35.4) 121 (29.0) 57 (32.9)
Unknown 1 (0.3) 1 (0.4) 1 (0.2) 1 (0.6)
Age of patients with comorbidities, years, mean (SD) [median] 62.2 (16.3) [62.0] 62.0 (15.1) [62.0] 62.8 (16.2) [63.5] 60.6 (15.2) [60.0]
Immunosuppressants/Immunomodulators in the 3 months
prior to hospitalization, n (%)
35 (9.6) 17 (7.2) 40 (9.6) 11 (6.4)
Type of lesion‡
Cellulitis/fasciitis 252 (69.4) 155 (65.4) 280 (67.1) 122 (70.5)
Abscess 77 (21.2) 45 (19.0) 86 (20.6) 34 (19.7)
Post-traumatic wound 40 (11.0) 18 (7.6) 48 (11.5) 10 (5.8)
Post-surgical wound 40 (11.0) 30 (12.7) 50 (12.0) 19 (11.0)
Diabetic leg ulcer 19 (5.2) 24 (10.1) 27 (6.5) 16 (9.2)
Peripheral vascular disease ulcer 14 (3.9) 20 (8.4) 19 (4.6) 14 (8.1)
Lesion extension >50 cm2 61 (16.8) 49 (20.7) 73 (17.5) 36 (20.8)
Lower extremities affected 227 (62.5) 180 (75.9) 265 (63.5) 134 (77.5)
Swelling/induration 239 (65.8) 173 (73.0) 273 (65.5) 132 (76.3)
Skin necrosis 28 (7.7) 35 (14.8) 38 (9.1) 24 (13.9)
Recurrent skin infection episode§ 75 (20.7) 55 (23.2) 83 (19.9) 43 (24.9)
Nosocomial infection 30 (8.3) 22 (9.3) 35 (8.4) 17 (9.8)
*Visit to hospital for current infection or date of diagnosis of infection for patients already hospitalized.
†As defined by the investigator.
‡Patients could be classified with more than one type of cSSTI lesion.
§Patients hospitalized again due to same cSSTI.
SD = standard deviation.
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with those who could not be evaluated, suggests that the
evaluated patients were slightly younger, less likely to be
female, and had fewer comorbidities, with a lower pro-
portion having diabetic leg ulcers, peripheral vascular
disease ulcers, fascia affected and skin necrosis. There
was also a lower proportion of patients with recurrent
skin infections in this group but no notable differences
in microbiological diagnosis (Additional file 1: Table S3).
Microbiological diagnosis
A microbiological diagnosis was available for around half
of the patients in this subanalysis; patients without anearly response were more likely to have a microbio-
logical diagnosis with both definitions (Table 2). Patients
with an early response were more likely to be infected
with a Gram-positive microorganism compared with
patients without (D1: 80.7% and 68.5%, respectively).
Difficult-to-treat microorganisms and strict anaerobic
bacteria were more frequently isolated from patients
without an early response compared to those with. For
methicillin-resistant Staphylococcus aureus (MRSA), this
was only true when early response was assessed by D1
(13.1% and 9.9%, respectively). The numbers of patients
with bacteraemia were low; however, a greater difference
was seen between patients with and those without early
Table 2 Microbiological diagnosis
Definition 1 Definition 2








n = 363 n = 237 n = 417 n = 173
Investigations or diagnostic test
Blood cultures 231 (63.6) 165 (69.6) 270 (64.7) 117 (67.6)
Superficial swab and culture 153 (42.1) 131 (55.3) 183 (43.9) 96 (55.5)
Needle aspiration 31 (8.5) 25 (10.5) 36 (8.6) 19 (11.0)
Surgical sample 38 (10.5) 37 (15.6) 48 (11.5) 25 (14.5)
Positive microbiological diagnosis 161 (44.4) 130 (54.9) 193 (46.3) 91 (52.6)
Gram-positive cocci* 130 (80.7) 89 (68.5) 156 (80.8) 56 (61.5)
Methicillin-sensitive Staphylococcus aureus 54 (33.5) 32 (24.6) 61 (31.6) 22 (24.2)
Methicillin-resistant Staphylococcus aureus 16 (9.9) 17 (13.1) 23 (11.9) 8 (8.8)
Coagulase-negative Staphylococcus 24 (14.9) 11 (8.5) 27 (14.0) 8 (8.8)
Streptococcus pyogenes (group A β-haemolytic streptococci) 10 (6.2) 6 (4.6) 13 (6.7) 2 (2.2)
Streptococcus agalactiae (group B β-haemolytic streptococci) 4 (2.5) 8 (6.2) 7 (3.6) 5 (5.5)
Other β-haemolytic streptococci† 13 (8.1) 7 (5.4) 14 (7.3) 4 (4.4)
Streptococcus pneumoniae 1 (0.6) 0 (0) 1 (0.5) 0 (0)
Enterococcus faecalis 11 (6.8) 6 (4.6) 12 (6.2) 4 (4.4)
Enterococcus faecium 4 (2.5) 3 (2.3) 5 (2.6) 2 (2.2)
Other Gram-positive bacteria‡ 4 (2.5) 5 (3.8) 4 (2.1) 5 (5.5)
Enterobacteriaceae§, other Gram-negative bacteria¶, other strict anaerobic bacteria** 53 (32.9) 46 (35.4) 60 (31.1) 37 (40.7)
Non-fermenting Gram-negative bacilli†† 16 (9.9) 15 (11.5) 20 (10.4) 11 (12.1)
Polymicrobial infections 47 (29.2) 29 (22.3) 53 (27.5) 19 (20.9)
Yeasts 2 (1.2) 3 (2.3) 2 (1.0) 3 (3.3)
Other microorganisms 4 (2.5) 1 (0.8) 4 (2.1) 1 (1.1)
Bacteraemia 20 (5.5) 22 (9.3) 27 (6.5) 12 (6.9)
*Includes subgroups below and Staphylococcus warnerii, Staphylococcus lugdugensis, Staphylococcus haemolyticus, Staphylococcus epidermidis, Staphylococcus spp.
non-aureus, Streptococcus mitis, Streptococcus constellatus, viridans Streptococcus, Group G streptococci, Streptococcus mitis, Enterococcus spp., unspecified
Gram-positive cocci.
†Includes S. dysgalactiae, Group C streptococci, microaerophilic streptococci, S. mileri, S. intermedius, S. anginosus, S. bovis.
‡Includes Bacillus anthracis, Corynebacterium spp., diphtheroids, Proprionibacterium spp., Lactobacillus spp., Clostridium spp., Gram-positive bacilli non-specified.
§Includes Proteus mirabilis, Escherichia coli, Klebsiella spp, Enterobacter spp, Citrobacter spp, Serratia marcescens, Providencia stuartii, Morganella morganii, Pantoea spp.).
¶Includes Neisseria spp, Aeromonas hydrophila, Pasteurella multocida.
**Includes Gemella morbillorum, Bacteroides fragilis, Peptostreptococcus spp., Prevotella melaninogenica, Porphyromonas spp.
††Includes Pseudomonas spp., Acinetobacter spp., Stentrophomonas maltophilia, Shweanella putrefacians.
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spectively; D2: 6.5% and 6.9%, respectively).
Treatment characteristics
Most patients received empiric first-line treatment (D1:
90.1% and 73.4% with and without early response, re-
spectively – Table 3) and the majority of treatments
were initiated on the first day of hospitalization. Around
half of patients received only one course of antibiotic ther-
apy (Additional file 1: Table S4). Treatment characteristics
were similar with both definitions.
There were few notable differences in antibiotic ther-
apy used, except that more patients with an early responsewere treated with amoxicillin–clavulanate as initial therapy,
compared with those without, and more patients without
an early response were treated initially with ampicillin–
sulbactam or piperacillin–tazobactam than those with
early response (Table 3).
Clinical outcomes and resource use
Clinical outcomes and resource use are detailed in
Table 4. ITM was high in all groups, but was higher in
patients without an early response, with almost half of
these requiring ITM (D1: 34.2% and 48.1% with and
without early response, respectively). Overall treatment
duration, incidence of surgery after diagnosis, reinfection
Table 3 Most frequent antibiotics used as initial therapy (monotherapy and combinations)
Definition 1 Definition 2
Antibiotic, n (%) Early responders Not-early responders Early responders Not-early responders
n = 363 n = 237 n = 417 n = 173
Empiric treatment 327 (90.1) 174 (73.4) 368 (88.2) 126 (72.8)
Amoxicillin–clavulanate 66 (18.2) 29 (12.2) 70 (16.8) 24 (13.9)
Piperacillin–tazobactam 20 (5.5) 20 (8.4) 24 (5.8) 16 (9.2)
Ampicillin–sulbactam 25 (6.9) 47 (19.8) 30 (7.2) 42 (24.3)
Cloxacillin 16 (4.4) 4 (1.7) 18 (4.3) 1 (0.6)
Clindamycin 14 (3.9) 3 (1.3) 15 (3.6) 0 (0)
Penicillins or combinations + fluoroquinolone 11 (3.0) 6 (2.5) 12 (2.9) 5 (2.9)
Cefuroxime 11 (3.0) 5 (2.1) 14 (3.4) 2 (1.2)
Fluoroquinolone 6 (1.7) 4 (1.7) 6 (1.4) 4 (2.3)
Daptomycin 11 (3.0) 4 (1.7) 11 (2.6) 4 (2.3)
Carbapenem 9 (2.5) 9 (3.8) 10 (2.4) 7 (4.0)
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renal failure) and mortality were also all higher in pa-
tients without an early response.
Economic outcomes and use of healthcare resources were
associated with Day 3 clinical response, regardless of theTable 4 Clinical outcomes and resource use
Definition 1
Clinical outcomes and resource use Early responder
n = 363
Initial treatment modification, n (%) 124 (34.2)
Overall treatment duration, days, mean (SD) [median] 10.8 (8.7) [9.0]
Length of hospital stay, days, mean (SD) [median] 14.3 (16.7) [9.0]
Surgery after diagnosis, n (%) 98 (27.0)
Reinfection or recurrence, n (%) 29 (8.0)
Admitted to ICU, n (%) 15 (4.1)
Time in ICU, days, mean (SD) [median] 4.4 (4.6) [3.5]
Acute renal failure, n (%) 2 (0.6)
Length of acute renal failure, days, mean (SD) [median] 3.5 (2.1) [3.5]
Blood pressure support, n (%)
Fluid resuscitation 20 (5.5)
Vasopressors 3 (0.8)
Invasive procedures 0
Septic shock, n (%) 3 (0.8)
Isolation required, n (%) 7 (1.9)
Parenteral nutrition, n (%) 9 (2.5)
Length of parenteral nutrition, days, mean (SD) [median] 10.7 (10.2) [6.0]
Home-based care after discharge, n (%) 45 (12.4)
Mortality, n (%) 5 (1.4)
ICU = Intensive care unit.definition used. Patients without early response to treatment
had a higher rate of admission to the intensive care unit
compared to patients with early response (D1: 16.0% and
4.1%, respectively) and a median 7 or 8 days’ longer hospital
stay. Findings were similar with both definitions (Table 4).Definition 2
s Not-early responders Early responders Not-early responders
n = 237 n = 417 n = 173
114 (48.1) 148 (35.5) 87 (50.3)
17.6 (15.3) [13.0] 11.3 (10.2) [9.0] 18.4 (14.7) [14.0]
22.8 (24.5) [16.0] 14.8 (17.3) [10.0] 24.3 (25.7) [18.0]
91 (38.4) 121 (29.0) 63 (36.4)
24 (10.1) 34 (8.2) 16 (9.2)
38 (16.0) 27 (6.5) 26 (15.0)
10.1 (15.3) [5.0] 6.6 (9.7) [4.0] 10.4 (16.4) [5.0]
14 (5.9) 4 (1.0) 12 (6.9)
20.5 (54.2) [4.0] 3.0 (1.7) [2.0] 22.0 (56.3) [4.5]
36 (15.2) 27 (6.5) 28 (16.2)
22 (9.3) 6 (1.4) 19 (11.0)
0 0 0
15 (6.3) 6 (1.4) 12 (6.9)
18 (7.6) 13 (3.1) 11 (6.4)
16 (6.8) 11 (2.6) 13 (7.5)
38.4 (71.3) [12.0] 11.6 (11.3) [6.0] 43.9 (77.8) [13.0]
31 (13.1) 54 (12.9) 20 (11.6)
9 (3.8) 6 (1.4) 8 (4.6)
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Many patients with cSSTI do not receive adequate first-
line treatment [5,6]. Our subanalysis found that early re-
sponse to treatment is associated with better clinical
outcomes and lower use of hospital resources. These re-
sults are consistent with previous findings. A retrospective
cohort analysis of ABSSSI patients in New Jersey showed
that the cost of care for patients without early response to
antibiotic treatment was >1.5-fold higher than for patients
with early response (p < 0.0001) and patients who did
not respond within 72 hours had an additional 3.7 days
of treatment (p < 0.0001) [12].
In an earlier retrospective study, inappropriate initial
therapy was associated with cSSTI caused by mixed path-
ogens or MRSA, or by pathogens other than S. aureus or
streptococci [13]; however, another study found that the
incidence of MRSA did not differ between groups [14]. In
our study, patients without an early response were more
likely to be infected with Gram-negative bacteria and an-
aerobes, whereas Gram-positive bacteria were more fre-
quently isolated from early responders.
The rate of ITM in our subanalysis was higher than
previously observed, with almost half of the patients
without an early response requiring initial treatment to
be changed. Importantly, ITM was highest in patients
who did not respond to treatment within 72 hours. The
majority of patients were treated empirically. Two large
multi-centre retrospective studies in the US have shown
that in patients hospitalized with cSSTI, initial treatment
failure is frequent (19.4–22.8%) [5,6]. Berger et al. also
showed that patients with initial treatment failure have
4- to 12-fold higher mortality rates, spend 4.1–7.3 additional
days in hospital and incur $11,995–$23,655 additional
inpatient costs [5]. Data from a smaller, single-centre,
retrospective study suggest inappropriate treatment is
associated with increased use of healthcare resources
(e.g. longer hospitalization) but not with clinical outcomes
such as mortality [14]; however, these associations may
vary depending on the type of cSSTI evaluated [13].
The observation that later response to treatment is as-
sociated with worse clinical outcomes and higher use of
healthcare resources highlights the need to identify pa-
tients less likely to respond early to treatment, in order
to improve care and limit complications. One of the ob-
jectives of this subanalysis was to compare the results ob-
tained with two definitions of early response, one of which
(D1) required resolution of fever within 72 hours [9]. The
other definition (D2) did not require fever resolution,
based on the fact that fever is not on the causal pathway
of the disease and that a requirement for fever presenta-
tion at baseline may exclude certain populations, such as
older patients, from participating in clinical trials [11].
The results were largely similar, but overall, D1 appeared
to provide more specific differentiation between patientswith and without early response, although the reason for
this difference is not apparent. Patients evaluated in our
subanalysis were younger and had fewer comorbidities
and less severe disease compared with those who could
not be evaluated. This highlights a limitation of our subana-
lysis, as the evaluated population may not be representative
of all patients in the REACH study. These observations
might reflect the requirement for fever at presentation as
an inclusion criterion for this subanalysis, which may ex-
clude certain populations from being assessed [11]. In this
study, information on fever resolution was unavailable in
the medical records of 39% of patients (slightly higher
than the rate of unavailable information for Q2, Q3, Q4
and Q5).
Another objective of the study was real-life observa-
tion of cSSTI in Europe, which by definition results in
the inclusion of a heterogeneous patient population with
associated limitations, but has enabled us to capture a pic-
ture of current practice which has highlighted real con-
cerns. There are no recent European treatment guidelines
for cSSTI. Treatment is often empiric and selection of
first-line treatment is highly variable. This may be driven
by a broad range of potential pathogens, the need to treat
often without a confirmed microbiological diagnosis, and
a large generic pool of treatment options [6]. The findings
of REACH confirm this, with 54 different initial antibiotic
regimens (monotherapy or combination) used and the
majority of patients treated empirically [10]. In addition,
although all patients in this study underwent a micro-
biological test, a large proportion of specimens were
superficial swabs and therefore the culture results may
largely reflect colonization. These are concerning findings
which suggest an improvement in antibiotic stewardship
is needed urgently, along with early identification of pa-
tients at increased risk, to optimize selection of the most
suitable antibiotic treatment.
In medical practice, Day 3 clinical endpoints can have
strong therapeutic relevance. Early indications of treat-
ment failure can guide antimicrobial treatment modifi-
cation within 72 hours, thus avoiding prolonged use of
inappropriate antimicrobials and/or help to recognize the
need for surgery. Evaluation at Day 3 of the clinical evolu-
tion (course) and availability of the results of initial cultures
can aid decisions to de-escalate treatment to a narrower-
spectrum agent or to switch from IV to oral therapy, evalu-
ate the need for surgery, and subsequently discharge a
patient based on clinical improvement. A number of re-
cent studies have incorporated the FDA-recommended
endpoint of response to antimicrobial treatment within 72
hours. In their retrospective analysis of data from the
CANVAS 1 and 2 clinical trials, Friedland et al. showed
that ceftaroline fosamil treatment for ABSSSI led to a
higher clinical response compared with vancomycin plus
aztreonam at this early endpoint [15]. The CANVAS trials
Garau et al. BMC Infectious Diseases  (2015) 15:78 Page 8 of 9employed stricter inclusion criteria for skin infections than
the REACH study, excluding diabetic foot ulcers and
necrotising infections. Recently, a clinical trial reported
the non-inferiority of tedizolid phosphate to linezolid for
ABSSSI at 48–72 hours [16]. In addition, a retrospective
analysis of vancomycin for treatment of MRSA blood-
stream infections found that lack of response at Day 3 was
the strongest predictor of end-of-treatment failure [17].
These findings suggest that Day 3 endpoints are useful ef-
ficacy endpoints in the design of clinical trials for anti-
microbial agents for treatment of cSSTI.
Conclusion
This retrospective analysis of observational data from
patients hospitalized with cSSTI highlights the real-life
significance of an early response to treatment in terms
of better clinical outcomes and reduced use of health-
care resources.
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